<DOC>
	<DOCNO>NCT01276847</DOCNO>
	<brief_summary>This two-part study . The purpose pilot study ( Part 1 ) optimize acquisition , handle shipping procedure skin biopsy obtain participant plaque psoriasis . No treatment administer . Part 2 include 2 cohort . In Cohort 1 , effect 16 week treatment either ustekinumab etanercept biomarkers lesional skin participant moderate severe psoriasis evaluate . In Cohort 2 , biomarkers lesional skin participant moderate severe psoriasis treat biologic therapy evaluate 16 week . The primary hypothesis treatment ustekinumab reduces messenger RNA ( mRNA ) expression gene interleukin 12 ( IL-12 ) pathway modulate interferon gamma ( IFN-γ ) .</brief_summary>
	<brief_title>A Study Assess Effect Ustekinumab ( Stelara® ) Etanercept ( Enbrel® ) Participants With Moderate Severe Psoriasis ( MK-0000-206 )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Is unlikely conceive ( female participant reproductive potential ) Part 2 Has diagnosis predominantly plaque psoriasis ≥ 6 monthsParts 1 2 Has plaquetype psoriatic lesion Target Lesion Score ( TLS ) score ≥ 6 hidden area body abdomen , thigh , low back buttock suitable biopsy Part 1 Is consider candidate phototherapy systemic therapy Part 2 Has Psoriasis Area Severity Index ( PASI ) score ≥ 12 Baseline Part 2 Has psoriasis body surface area ( BSA ) involvement ≥ 10 % Baseline Part 2 Has Physician 's Global Assessment ( PGA ) least moderate disease ( moderate , mark , severe ) Baseline Part 2 Is consider eligible accord tuberculosis ( TB ) screen criterion Part 2 Has nonplaque form psoriasis specifically erythrodermic psoriasis , predominantly pustular psoriasis , medicationinduced medicationexacerbated psoriasis , new onset guttate psoriasis Parts 1 2 Women childbearing potential pregnant , intend become pregnant ( within 6 month complete trial ) , lactate Parts 1 2 Has history neoplastic disease concurrent malignancy Part 2 Requires oral injectable corticosteroid trial Part 2 Have infection require treatment antibiotic within 2 week prior screen serious infection require hospitalization treatment IV antibiotic within 8 week prior screen Part 2 Has positive human immunodeficiency virus ( HIV ) test result , hepatitis B surface antigen , hepatitis C test result Part 2 Has receive live virus vaccination within 4 week prior screen intend receive live virus vaccination trial Part 2 Has previous exposure agent target IL12 and/or IL23 ( e.g . ustekinumab ) Part 2 Has prior exposure tumor necrosis factor ( TNF ) antagonists ( e.g . infliximab , etanercept , golimumab , adalimumab ) discontinue due lack efficacy adverse effect Part 2 Has treat medication associate Progressive Multifocal Leukoencephalopathy ( PML ) , efalizumab ( Raptiva ) natalizumab ( Tysabri ) Part 2 Has take immunosuppressive agent ( e.g . corticosteroid , methotrexate , azathioprine , cyclosporine ) treatment condition Psoriasis within 4 week screen Part 2 Is currently take prohibit medication unwilling washout medication ( ) indicate timeframe prior screen duration study Part 2</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>Stelara</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Enbrel</keyword>
</DOC>